TRAP1 increases tumor cell proliferation and invasion but also provides researchers with a potential new therapeutic target.
A protein called TRAP1 - an important regulator of energy production in healthy and cancerous cells - is an important driver of prostate cancer and appears to be a valuable therapeutic target for the disease. //
‘TRAP1 is a chaperone protein that is structurally similar to heat shock protein 90, which is found in larger amounts in the mitochondria of cancer cells.’
Mitochondria
are known as the powerhouse of the cells because of their role in energy
production, and in recent years, research has shown that different tumors are
able to manipulate genes and proteins responsible for energy production in
order to help them survive. TRAP1 is a chaperone protein that is structurally similar to heat shock protein 90 (HSP90), which is found in larger amounts in the mitochondria of cancer cells. In a prior study, Dario C. Altieri, M.D., president and CEO of The Wistar Institute, director of The Wistar Institute Cancer Center, the Robert & Penny Fox Distinguished Professor, and colleagues bred mice with the TRAP1 protein "knocked out" to determine what impact it may have on disease. These special mice lived longer and experienced fewer age-related illnesses, suggesting that the protein played an important role in disease.
"In our prior study, while we had evidence that hinted at TRAP1's role in tumor growth, we lacked the direct evidence we needed to define the role of this protein in prostate cancer development," Altieri said.
Advertisement
Advertisement
The combination of increased TRAP1 coupled with the loss of PTEN resulted in aggressive, early-onset invasive prostate cancer, according to the study. Altieri and colleagues found increased tumor cell proliferation, inhibition of apoptosis (a form of programmed cell death that is thought to halt the progression of tumor cells), and increased epithelial cell invasion. These findings suggest that TRAP1 has a role in promoting the mitochondrial "fitness" of a prostate tumor, making it more aggressive and less responsive to treatment.
"What is exciting about these findings is the fact that we believe TRAP1 is a druggable target," Altieri said. "We are continuing to advance our promising research and development program aimed at targeting the mitochondria in tumors."
Source-Eurekalert